Herantis Pharma Plc.

Herantis Pharma Plc is a forward-thinking clinical-stage biotechnology company dedicated to developing innovative, disease-modifying therapies for Parkinson’s disease. With a commitment to advancing neurological care, Herantis Pharma Plc is focused on creating impactful treatments that improve patient outcomes and quality of life. The company's lead product, HER-096, represents a significant advancement in the treatment of Parkinson’s disease, offering disease-modifying potential with the convenience of subcutaneous administration.

Located in Espoo, Southern Finland at Bertel Jungin aukio 1, 02600, FI, Herantis Pharma Plc is driven by a passion for scientific excellence and a dedication to addressing unmet medical needs in the field of neurodegenerative diseases. The ongoing Phase 1b clinical trial, assessing the safety, tolerability, and pharmacokinetics of repeated subcutaneous doses of HER-096, exemplifies Herantis Pharma Plc's commitment to rigorous research and development. With the support of organizations such as the Michael J. Fox Foundation for Parkinson’s Research and The Parkinson’s Virtual Biotech, Herantis Pharma Plc is poised to make significant contributions to the future of Parkinson’s disease treatment.

Herantis Pharma Plc is dedicated to pioneering advancements in biotechnology and transforming the landscape of Parkinson's disease therapy. The company continues to push the boundaries of medical innovation, striving to deliver breakthrough treatments that enhance the lives of individuals affected by this challenging condition. We invite the management team at Herantis Pharma Plc to create a customized and exclusive company showcase and product listing on our platform, further highlighting your achievements and contributions to the biotechnology industry.